Open AccessRole of tenofovir and telbivudine in treatment of hepatitis B related acute on chronic liver failure
Author(s) -
Debraj Malakar,
Mamun Al Mahtab,
Abul Hayat Manik,
Shamsul Alam,
Debasish Das,
Ayub Al Mamun,
Md. Sakirul Islam Khan,
Zakiur Rahman,
Salimur Rahman,
Sheikh Mohammad Fazle Akbar
Publication year - 2021
Publication title -
journal of family medicine and primary care
Language(s) - English
Resource type - Journals
eISSN - 2278-7135
pISSN - 2249-4863
DOI - 10.4103/jfmpc.jfmpc_2302_20
Subject(s) - telbivudine , medicine , gastroenterology , creatinine , hepatitis b , entecavir , tenofovir , liver function , clinical endpoint , liver disease , chronic hepatitis , hepatitis b virus , model for end stage liver disease , lamivudine , randomized controlled trial , immunology , liver transplantation , virus , transplantation , human immunodeficiency virus (hiv)
ACLF is characterized by acute deterioration of liver function in patients with chronic liver disease. HBV is one of the most important causes of both acute insult and underlying chronic liver disease in ACLF. Reactivation of HBV is one of the common causes of ACLF in our region. ACLF requires multiple organ support and is associated with high short and medium term mortality. This is the reason why early, rapid reduction of HBV DNA is essential in treating ACLF-B.